Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment's ...
The Appraisal Committee considered evidence submitted by the manufacturer of mannitol and a review of this submission by the Evidence Review Group (ERG). DPM-CF-301 included 295 patients (190 adults) ...
CARY, N.C., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group ...
Prior to prescribing Bronchitol, the Bronchitol Tolerance Test must be administered and performed under the supervision of a health care professional. Bronchitol ® (mannitol inhalation powder) is now ...
The US Food and Drug Administration's (FDA's) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 9 to 7 on Wednesday to recommend mannitol inhalation powder (Bronchitol, Chiesi) for oral ...
Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment's ...
The Department of Health has asked the National Institute for Health and Clinical Excellence (NICE) to produce guidance on using mannitol in the NHS in England and Wales. The Appraisal Committee has ...
CARY, N.C., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group ...
Including inhaled dry powder mannitol to standard therapy for cystic fibrosis gave rise to sustained progress in lung function for up to 52 weeks, according to a new study. Along with the treatment's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback